<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="1312">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 10, 2022</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05231785</url>
  </required_header>
  <id_info>
    <org_study_id>ALN-APP-001</org_study_id>
    <secondary_id>2021-003198-74</secondary_id>
    <nct_id>NCT05231785</nct_id>
  </id_info>
  <brief_title>A Study to Evaluate the Safety and Tolerability of ALN-APP in Patients With EOAD</brief_title>
  <official_title>A Randomized, Double-blind, Placebo-controlled Single Ascending Dose and Open-label Multi-dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Intrathecally Administered ALN-APP in Adult Patients With Early-onset Alzheimer's Disease (EOAD)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Alnylam Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Alnylam Pharmaceuticals</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the safety, tolerability, pharmacodynamics (PD) and&#xD;
      pharmacokinetics (PK) of single intrathecal (IT) doses of ALN-APP in adult patients with&#xD;
      early-onset Alzheimer's Disease (EOAD). Maximum treatment duration for Part A: single dose.&#xD;
      Maximum treatment for Part B: 12 months.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 4, 2022</start_date>
  <completion_date type="Anticipated">July 2025</completion_date>
  <primary_completion_date type="Anticipated">July 2025</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Maximum treatment duration for Part A: single dose. Maximum treatment for Part B: 12 months.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Part A: Frequency of Adverse Events</measure>
    <time_frame>Up to 14 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Part B: Frequency of Adverse Events</measure>
    <time_frame>Up to 24 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Part A and Part B: Change from Baseline in Levels of Cerebrospinal Fluid (CSF) Soluble Amyloid Precursor Protein Alpha (sAPPα) and Soluble Amyloid Precursor Protein Beta (sAPPβ)</measure>
    <time_frame>Part A up to 14 months; Part B up to 24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part A and Part B: Area Under the Plasma Concentration-time Curve (AUC) of ALN-APP and of Potential Metabolites</measure>
    <time_frame>Part A up to 14 months; Part B up to 24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part A and Part B: Maximum Observed Plasma Concentration (Cmax) of ALN-APP and of Potential Metabolites</measure>
    <time_frame>Part A up to 14 months; Part B up to 24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part A: Fraction of ALN-APP and Potential Metabolites Excreted in the Urine (fe)</measure>
    <time_frame>Up to 14 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part A and Part B: Concentration at Time 't' (Ct) of ALN-APP and Potential Metabolites</measure>
    <time_frame>Part A up to 14 months; Part B up to 24 months</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Early-Onset Alzheimer Disease</condition>
  <arm_group>
    <arm_group_label>Part A: ALN-APP</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will be administered a single dose of ALN-APP.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part A: Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Participants will be administered a single dose of placebo.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part B:</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will be administered multiple doses of ALN-APP.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ALN-APP</intervention_name>
    <description>ALN-APP will be administered intrathecally (IT)</description>
    <arm_group_label>Part A: ALN-APP</arm_group_label>
    <arm_group_label>Part B:</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo will be administered IT</description>
    <arm_group_label>Part A: Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Has mild cognitive impairment or mild dementia due to EOAD&#xD;
&#xD;
          -  Has Clinical Dementia Rating (CDR) global score 0.5 or 1.0 and Mini Mental State&#xD;
             Examination (MMSE) &gt;20&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Has Non-Alzheimer's disease dementia&#xD;
&#xD;
          -  Has alanine aminotransferase (ALT) or aspartate aminotransferase (AST) &gt;2×upper limit&#xD;
             of normal (ULN)&#xD;
&#xD;
          -  Has estimated glomerular filtration rate (eGFR) &lt;45 mL/min/1.73m^2 at Screening&#xD;
&#xD;
          -  Has recently received an investigational agent&#xD;
&#xD;
          -  Has recent treatment with amyloid-targeting antibody&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Director</last_name>
    <role>Study Director</role>
    <affiliation>Alnylam Pharmaceuticals</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Alnylam Clinical Trial Information Line</last_name>
    <phone>1-877-ALNYLAM</phone>
    <email>clinicaltrials@alnylam.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Alnylam Clinical Trial Information Line</last_name>
    <phone>1-877-256-9526</phone>
    <email>clinicaltrials@alnylam.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Clinical Trial Site</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46202</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Clinical Trial Site</name>
      <address>
        <city>Aurora</city>
        <state>Ontario</state>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Clinical Trial Site</name>
      <address>
        <city>Amsterdam</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Clinical Trial Site</name>
      <address>
        <city>London</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>Netherlands</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2022</verification_date>
  <study_first_submitted>January 30, 2022</study_first_submitted>
  <study_first_submitted_qc>January 30, 2022</study_first_submitted_qc>
  <study_first_posted type="Actual">February 9, 2022</study_first_posted>
  <last_update_submitted>November 7, 2022</last_update_submitted>
  <last_update_submitted_qc>November 7, 2022</last_update_submitted_qc>
  <last_update_posted type="Actual">November 9, 2022</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>EOAD</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Alzheimer Disease</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

